Mounjaro Treatment for Weight Loss
Weight loss medicine experienced a seismic shift when tirzepatide entered clinical practice. Unlike anything available before, this dual-action molecule targets two gut hormones simultaneously, and the results from large-scale trials left even the most cautious researchers impressed. If you keep encountering Mounjaro in every article about weight loss injections, there is a solid reason for that.
At Nikky Bawa Medi Salon, we offer a medically supervised Mounjaro treatment for weight loss programme at our Bhopal clinic. Dr. Sahiba Bawa oversees every protocol, ensuring the treatment aligns with your metabolic profile, health background, and weight management goals. Bhopal’s position as a growing hub for advanced medical aesthetics means patients no longer need to travel to Delhi or Mumbai for cutting-edge weight management therapies.
Dr. Bawa’s training in Seoul, South Korea, one of the world’s most advanced markets for aesthetic and metabolic medicine, ensures internationally benchmarked care with the personalised attention a boutique clinic provides.
We operate from Ajay Tower, E 5/1, Bittan Market, Bhopal, Madhya Pradesh 462016.
What Is Mounjaro and How Does It Work?
How does Mounjaro work differently from other weight loss medications?
The active ingredient, tirzepatide, activates two incretin hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most currently available weight loss medications target only the GLP-1 pathway. Tirzepatide hits both — which is why the results consistently outperform single-hormone approaches.
The dual-receptor mechanism: what's actually happening inside your body
- GIP receptor activation improves insulin sensitivity and may enhance energy expenditure in adipose tissue, supporting healthier fat distribution patterns
- GLP-1 receptor activation suppresses appetite through central nervous system pathways, reducing caloric intake without willpower dependency
- The combined dual-receptor engagement produces synergistic effects that surpass single-hormone approaches in every head-to-head trial conducted to date
- Gastric motility slows, extending post-meal satiety and reducing overall caloric intake across the entire day
- Hepatic glucose production decreases, improving fasting blood sugar levels and reducing the metabolic burden on the pancreas
The GIP pathway is what sets tirzepatide apart from semaglutide. Research suggests GIP receptor activation may redirect fat cells to store circulating lipids in subcutaneous depots rather than as visceral fat — the metabolically dangerous fat surrounding internal organs. This explains part of tirzepatide’s superior body composition outcomes.
Tirzepatide was developed by Eli Lilly and received FDA approval for Type 2 diabetes in 2022 under the brand name Mounjaro. The SURMOUNT programme established its efficacy specifically for obesity treatment. At the highest dose (15 mg weekly), tirzepatide produced weight loss of up to 22.5% of body weight over 72 weeks. (Jastreboff et al., New England Journal of Medicine, 2023)
Gallery
Mounjaro vs Ozempic: Which One Should You Choose?
| Feature | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Hormone targets | GIP + GLP-1 (dual) | GLP-1 only |
| Maximum weight loss | Up to 22.5% body weight | Up to 15–17% body weight |
| Injection frequency | Once weekly | Once weekly |
| Dose range | 2.5 mg to 15 mg | 0.25 mg to 2.0 mg |
| Head-to-head result | 47% more weight loss | Reference arm |
| Common side effects | Nausea, diarrhoea, vomiting | Nausea, diarrhoea, constipation |
| Availability in India | Limited, growing | More widely available |
| Monthly cost (INR) | ₹8,000 – 22,000 | ₹4,000 – 20,000 |
The SURMOUNT-5 trial, a direct head-to-head comparison published in 2025, showed tirzepatide produced 47% more weight loss than semaglutide over 72 weeks when both were titrated to maximum tolerated doses.
(Aronne et al., NEJM 2025)
In simple terms:
Tirzepatide caused 20.2% average weight loss vs semaglutide’s 13.7% — making it 47% more effective over 72 weeks in 751 obese adults using highest tolerated doses (tirzepatide 15 mg, semaglutide 2.4 mg weekly).
“The dual-incretin approach of tirzepatide delivers superior efficacy in weight reduction compared to single-receptor agonists.” — Louis Aronne, MD (SURMOUNT-5, NEJM 2025)
In simple terms:
Tirzepatide works like
two hunger hormones working together (GLP-1 + GIP) to make you feel fuller longer, crave less food, and burn more fat — compared to semaglutide’s one-hormone approach.
This dual action led to 47% more weight loss (20.2% vs 13.7% of body weight over 72 weeks).
Effective weight management pharmacotherapy is especially critical for this demographic.
Dr. Shashank Joshi, leading endocrinologist and past president of the Indian Thyroid Society, has highlighted the particular relevance of dual-incretin therapies for the Indian population — which carries a disproportionately high genetic predisposition to insulin resistance and Type 2 diabetes at lower BMI thresholds than Western populations. (Dr. Shashank Joshi profile, Wikipedia; Indian T2D genetic predisposition studies)
Patient Review
Who Can Benefit from Mounjaro?
Am I a candidate for tirzepatide?
You may be suitable for Mounjaro if:
- Your BMI is 30 or above (WHO obese classification) and you are eligible for pharmacological weight management
- Your BMI is 27 or above with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea
- You have not achieved sufficient weight loss through structured lifestyle modifications despite genuine, sustained effort
- You do not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- You are not pregnant, breastfeeding, or planning pregnancy within six months of starting treatment
Indian dietary considerations: Bawa works with patients to design culturally appropriate dietary plans that meet protein requirements for lean mass preservation using plant-based sources — dal preparations, paneer, soya, Greek yoghurt, and strategically combined grain-legume combinations that provide complete amino acid profiles.
Dr. Bawa conducts comprehensive screening before initiating any tirzepatide protocol: metabolic bloodwork, thyroid function, pancreatic markers, body composition analysis, and detailed medical history review.
On the economics of treatment: When evaluating cost, consider the downstream savings from significant weight loss — reduced medication costs for hypertension, diabetes, and dyslipidaemia; fewer hospital visits; improved workplace productivity.
For many patients, the investment in a structured weight management programme pays for itself within 12–18 months through reduced healthcare spending elsewhere.
Reviews
Mounjaro Injection Price in India
The Mounjaro injection price in India is currently higher than Ozempic due to limited supply channels and recent market entry. Generic tirzepatide is not yet available in India, so branded Mounjaro remains the only option. Costs may decrease as supply chains mature and additional manufacturers enter the market.
At Nikky Bawa Medi Salon, we outline the complete financial commitment before starting treatment. Consultation fees, bloodwork, and follow-up assessments are included in our programme pricing.
The Treatment Journey: What to Expect Week by Week
| Phase | Weeks | Dose | Expected Changes | Key Milestones |
|---|---|---|---|---|
| Adjustment | 1–4 | 2.5 mg | GI adaptation, appetite drops | Appetite reduced by day 7–10 |
| Escalation | 5–8 | 5 mg | 2–4 kg loss, cravings weaken | Energy levels improve |
| Momentum | 9–16 | 7.5–10 mg | Body changes visible | Waist down 3–6 cm |
| Consolidation | 17–24 | 10–15 mg | 8–15% total weight loss | Sleep and energy improve |
| Maintenance | 25+ | Optimised | Stabilisation, habits set | Long-term plan in place |
Starting Mounjaro requires patience and realistic expectations. Your body needs time to adapt to dual-hormone activation:
Weeks 1–4 (Adjustment): Treatment begins at 2.5 mg once weekly. The primary goal is gastrointestinal adaptation. Nausea, mild diarrhoea, and reduced appetite are the most common effects. These typically diminish by the end of week three. Most patients notice appetite reduction by day 7–10.
Weeks 5–8 (Escalation): The dose increases to 5 mg. Weight loss accelerates. Patients typically lose 2–4 kg as caloric intake naturally decreases. Energy levels often improve as blood sugar stabilises. Cravings for high-calorie foods become noticeably weaker.
Weeks 9–16 (Momentum): Further escalation to 7.5–10 mg depending on tolerance and clinical response. Body composition changes become visible in the mirror and on measurement. Waist circumference typically decreases by 3–6 cm. Metabolic markers including HbA1c and fasting glucose begin to shift favourably.
Months 4–6 (Consolidation): Higher doses of 10–15 mg if clinically appropriate. Sustained weight loss of 8–15% of starting body weight. Patients report improved sleep quality, reduced joint pain, and better energy throughout the day.
Weight loss plateaus: They are expected and physiologically normal. As the body loses weight, its basal metabolic rate decreases and hunger hormones adapt — an evolutionary response. Tirzepatide partially counteracts these mechanisms, but plateaus can still occur around months 4–5. Our approach: reassess dietary intake, adjust physical activity toward resistance training, and fine-tune the dose where appropriate.
Throughout the entire programme, Dr. Bawa monitors progress through monthly consultations, bloodwork at 8-week intervals, and body composition analysis to ensure fat loss is occurring without excessive lean mass reduction.
Mounjaro Alternatives: Other Paths to Medical Weight Loss
Tirzepatide isn’t the right fit for every patient. Supply limitations, cost, or medical contraindications may direct you toward Mounjaro alternatives:
- Semaglutide (Ozempic): The GLP-1-only option with the most extensive clinical data and wider availability in India. Produces 15–17% weight loss in clinical trials.
- Liraglutide (Saxenda): A daily injectable GLP-1 agonist with a well-established safety profile over more than a decade. Requires daily rather than weekly injection.
- Lipotropic and MIC injections: Vitamin and amino acid formulations that support hepatic fat metabolism. Less appetite suppression but a useful metabolic adjunct.
- Orlistat: An oral lipase inhibitor that reduces dietary fat absorption by approximately 30%. Older technology but effective when combined with a reduced-fat diet.
- EMS body sculpting: Non-invasive electromagnetic muscle stimulation that builds lean mass while reducing localised fat. No systemic medication effects.
Sequential therapy is also an option. Rather than committing to a single medication indefinitely, some patients benefit from rotating agents based on response and tolerance — starting with semaglutide, transitioning to tirzepatide for enhanced efficacy, then tapering to a lower-cost maintenance option once target weight is achieved. Dr. Bawa adjusts the pharmacological strategy as your metabolic profile evolves.
Side Effects and Safety Monitoring
What to expect during dose escalation?
Tirzepatide has a side effect profile broadly similar to other incretin-based therapies, with gastrointestinal symptoms dominating the early treatment period.
- Nausea, vomiting, diarrhoea, and constipation occur in 15–30% of patients during dose escalation phases. These rates decline substantially as the body adjusts, typically within 4–6 weeks of reaching a stable dose.
- Injection site reactions are mild and infrequent.
- Some patients report a reduced appetite for high-fat meals — a pharmacological effect many find helpful for maintaining dietary discipline.
Serious adverse events remain rare. Pancreatitis, gallbladder disease, and acute kidney injury have been reported in post-marketing surveillance but occur in less than 1% of treated patients. A comprehensive 2024 safety review across all SURMOUNT trials confirmed no new safety signals. (FDA Post-Market Safety Review, 2024)
Our monitoring protocol: Bloodwork at baseline, 8 weeks, 16 weeks, and 24 weeks — covering pancreatic enzymes, liver function, kidney markers, and thyroid function. Any abnormality triggers immediate clinical evaluation.
Note on exercise during treatment: As calorie intake drops substantially, excessive cardiovascular exercise risks lean mass depletion. Our recommended approach prioritises resistance training (even 2–3 sessions per week using bodyweight or light weights) over prolonged cardio sessions, with walking encouraged for cardiovascular health and mental wellbeing.
How Mounjaro Affects Body Composition
Weight loss isn’t just about the number on the scale. What you’re losing matters enormously. Fat loss is the goal. Muscle loss is the risk that must be managed.
The SURMOUNT-1 body composition sub-study, published in 2024, used DEXA scanning to measure changes precisely. Approximately 75% of weight lost on tirzepatide was fat mass, with the remaining 25% being lean mass. (Journal of Clinical Endocrinology & Metabolism, 2024) This ratio is significantly better than what is typically observed with calorie-restriction diets alone, where lean mass loss can reach 30–40% of total weight lost.
To protect muscle mass during treatment, we recommend:
- Protein intake of 1.2–1.6 g per kilogram of ideal body weight daily
- Regular resistance training (even bodyweight exercises count)
- Periodic body composition assessments to track the fat-to-lean ratio over time
- A minimum of 2–3 litres of water daily, with electrolyte supplementation during the first month when GI symptoms are most likely
Mental health support: As the body changes rapidly, patients sometimes experience a dissonance between their physical appearance and their internal body image. Our team provides supportive guidance throughout the process and can refer patients to psychological professionals when body image concerns require dedicated therapeutic attention.
How Effective Is Mounjaro for Weight Loss?
Mounjaro is currently the most effective medical weight loss treatment available. Clinical trials demonstrate weight loss of up to 22.5% of body weight at the maximum dose over 72 weeks. It works by activating both GIP and GLP-1 hormone receptors, producing stronger appetite suppression and metabolic improvements than single-hormone medications like semaglutide. A head-to-head trial showed 47% greater weight loss compared to Ozempic. Results depend on dose, treatment duration, dietary changes, and physical activity levels.
Start with a Consultation
If you have tried diets, workouts, and still feel stuck, it is time for a different approach. Come in for a consultation. No pressure. No commitments. Just a focused discussion with a doctor who understands medical weight management. Reach out today to get started.
Your body is not the problem. The approach often is. With the right intervention, change becomes achievable and sustainable.
Book your consultation at Nikky Bawa Medi Salon, Bittan Market, Bhopal. Dr. Sahiba Bawa will evaluate your health background, map your weight loss goals, and design a Mounjaro treatment protocol that fits your body and your routine. Contact us to book your appointment.
Frequently Asked Questions
Mounjaro activates two hormone receptors (GIP and GLP-1), while Ozempic targets only GLP-1. This dual action produces greater weight loss in clinical trials — tirzepatide achieving up to 22.5% body weight reduction compared to 15–17% for semaglutide. The SURMOUNT-5 head-to-head trial confirmed 47% more weight loss with tirzepatide.
Yes. Switching is clinically appropriate and sometimes recommended when semaglutide produces insufficient results. The transition requires a washout period of 2–4 weeks (both medications have a ~7-day half-life, so residual levels persist for weeks after the last injection) and careful dose adjustment to minimise compounded side effects. Dr. Bawa manages the transition protocol to maintain treatment momentum.
Yes. Nikky Bawa Medi Salon stocks Mounjaro and manages the complete treatment protocol in-house. Supply can fluctuate due to national distribution patterns, so we recommend confirming availability when booking your initial consultation.
Yes. While tirzepatide significantly reduces appetite, the nutritional quality of your remaining food intake matters for health outcomes and body composition. We provide dietary guidance that ensures adequate protein (for muscle preservation), fibre (for digestive health), and micronutrient intake as your total calorie consumption naturally decreases.
Clinical protocols recommend at least 24 weeks of treatment to achieve meaningful and sustained weight loss. Many patients continue for 12 months or longer. The decision to continue, taper, or discontinue is made collaboratively between you and Dr. Bawa based on progress data.
Schedule a Consultation
Ph: +91 9893544778
Address: Nikky Bawa Medi Salon
BITTAN MARKET, 1st Floor Ajay TowerE-5/1, Arera Colony
Bhopal Madhya Pradesh 462003